Licenses enable Enigma to conduct and commercialize HybProbe real-time PCR tests.

Enigma Diagnostics signed two patent license agreements with Roche Molecular Systems (RMS). The licenses will provide Enigma full access under patents owned or licensed by RMS and its affiliates to practice HybProbe real-time PCR chemistry.

The arrangement will also allow Enigma to commercialize HybProbe diagnostic PCR tests for human and veterinary in vitro diagnostics on a worldwide basis. This complements Enigma’s existing license under patents owned by Celera Diagnostics for real-time PCR thermal cyclers.

Enigma is currently developing a series of multiplexed, HybProbe assays for infectious diseases including chlamydia, influenza, and MRSA. These tests will be combined with Enigma’s fully automated real-time PCR system, the Enigma ML, to enable one-step molecular testing at point of care.

Previous articleParion Obtains $850K Biodefense Grant
Next articleRoche Diagnostics to Offer Fujirebio Diagnostics’ Ovarian Cancer Test